RADNOR, Pa., Dec. 21, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against PACS Group, Inc. ("PACS") (NYSE: PACS). The lawsuit is brought on behalf of investors who purchased or otherwise acquired PACS: 1) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with PACS' April 11, 2024 initial public o ...

NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PACS Group, Inc. ("PACS" or the "Company") (NYSE: PACS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether PACS and certain of its officers and/or dir ...

NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against PACS Group, Inc. (NYSE: PACS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in PACS, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/pacs-group-inc. Investors have until January 13, 2025, to ask the Court to be appointed to lead t ...

NEW YORK, Dec. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PACS Group, Inc. (NYSE: PACS).Shareholders who purchased shares of PACS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacs-group-inc-loss-submission-form/?id=117274&from=4CLASS PERIOD: This lawsuit is on  beh ...

SAN DIEGO, Dec. 18, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of PACS Group, Inc. (NYSE: PACS): (i) securities between April 11, 2024 and November 5, 2024, inclusive (the "Class Period"); and/or (ii) common stock pursuant and/or traceable to PACS Group's registration statement issued in connection with PACS Group's April 11, 2024 initial public offering ("IPO"), have until Monday, January 13, 2025 to seek appointment as lead plaintiff of the PACS Group clas ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PACS Group Inc. common stock during its IPO and subsequent securities offerings about a class action lawsuit with a lead plaintiff deadline of January 13, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased PACS common stock during the IPO or between April 11, 2024, and November 5, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that PACS engaged in misleading practices, including submitting false Medicare claims that significantly inflated its operating and net income from 2020 to 2023 [5]. Group 2: Allegations Against PACS - The lawsuit alleges that PACS was involved in a scheme to bill for unnecessary therapies to Medicare and falsified documentation related to licensure and staffing [5]. - As a result of these actions, the positive statements made by PACS regarding its business operations were materially misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

RADNOR, Pa., Dec. 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against PACS Group, Inc. ("PACS") (NYSE: PACS). The lawsuit is brought on behalf of investors who purchased or otherwise acquired PACS: 1) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with PACS' April 11, 2024 initial public o ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PACS Group To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PACS Group between (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's April 11, 2024 initial public offering ("IPO" or the "Offering"); and/or  (b) all pe ...

Core Viewpoint - A lawsuit has been filed against PACS Group, Inc. and its senior executives for potential violations of federal securities laws, following allegations of fraudulent practices related to Medicare benefits [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Manchin v. PACS Group, Inc., et al., No. 24-cv-08636 [2]. - Investors have until January 13, 2025, to request to lead the case [2]. Group 2: Allegations Against PACS - PACS is alleged to be one of the largest operators of skilled nursing facilities in the U.S., claiming to have a successful turnaround strategy that was actually based on illicitly accessing Medicare benefits [3]. - Hindenburg Research published a report alleging that PACS abused a COVID-era waiver to access Medicare benefits for thousands of patients, which they claim drove over 100% of PACS's operating and net income from 2020 to 2023 [4]. Group 3: Stock Price Impact - Following the allegations, PACS's stock price fell significantly, dropping 27.8% from $42.94 on November 1, 2024, to $31.01 on November 4, 2024, and then further declining 38.8% from $29.54 on November 5, 2024, to $18.09 on November 6, 2024 [4].

Core Viewpoint - A securities class action lawsuit has been filed against PACS Group, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial performance during the class period from April 11, 2024, to November 5, 2024 [1]. Group 1: Allegations Against PACS Group, Inc. - The lawsuit claims that PACS engaged in a scheme to submit false Medicare claims, which accounted for over 100% of its operating and net income from 2020 to 2023 [3]. - It is alleged that PACS billed for thousands of unnecessary respiratory and sensory integration therapies to Medicare [3]. - The company is accused of falsifying documentation related to licensure and staffing, leading to misleading positive statements about its business prospects [3]. Group 2: Legal Process and Investor Actions - Investors who purchased PACS stock during the class period can seek to be appointed as lead plaintiffs by January 13, 2025, or remain absent class members [4]. - The lead plaintiff will represent the interests of all class members and select counsel to direct the litigation [4]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the case, known for prosecuting class actions and recovering billions for victims of corporate misconduct [5].